AORT
Artivion, Inc. · NYSE
- Sector Health Technology
- Industry Medical Specialties
- Website artivion.com
- Employees(FY) 1300
- ISIN US2289031005
Performance
+0.71%
1W
+3.9%
1M
+22.51%
3M
+27.81%
6M
+66.83%
YTD
+65.35%
1Y
Profile
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent and graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.
Technical Analysis of AORT 2024-12-10
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-12-09 08:00
- 2024-12-08 19:00
- 2024-12-03 19:00
AORT: Rating increased to a HOLD(Argus Research)
- 2024-11-30 09:08
- 2024-11-26 19:00
AORT: Raising target price to $23.00(Argus Research)
- 2024-11-12 19:00
AORT: What does Argus have to say about AORT?(Argus Research)
- 2024-11-09 07:03
Artivion Third Quarter 2024 Earnings: Beats Expectations(Simply Wall St.)
- 2024-11-07 16:05
- 2024-11-07 03:05
- 2024-11-05 19:00
AORT: Raising target price to $22.00(Argus Research)
- 2024-11-05 16:15
- 2024-11-05 03:15
- 2024-10-24 16:15
- 2024-10-24 04:15
- 2024-10-10 16:10
- 2024-10-10 04:10
- 2024-10-08 20:00
AORT: Lowering target price to $27.00(Argus Research)
- 2024-09-26 09:32
Those who invested in Artivion (NYSE:AORT) a year ago are up 61%(Simply Wall St.)
- 2024-09-02 09:58
Is Now An Opportune Moment To Examine Artivion, Inc. (NYSE:AORT)?(Simply Wall St.)
- 2024-08-27 20:00
AORT: Raising target price to $30.00(Argus Research)
- 2024-08-20 20:00
AORT: Raising target price to $28.00(Argus Research)
- 2024-08-11 10:25
A Look At The Intrinsic Value Of Artivion, Inc. (NYSE:AORT)(Simply Wall St.)
- 2024-08-08 16:05
- 2024-08-08 04:05
- 2024-08-05 04:10
- 2024-07-25 16:10
- 2024-07-25 04:10
- 2024-07-23 20:00
AORT: Raising target price to $29.00(Argus Research)
- 2024-07-16 20:00
AORT: Rating increased to a HOLD(Argus Research)
- 2024-07-09 20:00
AORT: What does Argus have to say about AORT?(Argus Research)
Page 1 of 5
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.